Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.03 -0.50%

-$0.14 today

Market cap
$465.03M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 8.33M

Average 1.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$69.81M

FY 2025 · Annual

Investing Cash Flow

$97.48M

FY 2025 · Annual

Financing Cash Flow

$248.89M

FY 2025 · Annual

+62.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Depreciation & Amortization245.7K533.13K1.07M1.43M1.89M
Deferred Income Tax(310.26K)0000
Stock-Based Compensation2.97M4.46M7.39M9.77M17.23M
Change in Working Capital182.34K28.75M(11.75M)(10.78M)12.2M
Accounts Receivables(391.75M)(155.83K)(9.82M)3.5K10.31M
Inventory391.75M0000
Accounts Payables991.17K1.21M1.33M1.94M5.98M
Other Working Capital(808.83K)27.7M(3.25M)(12.73M)(4.09M)
Other Non-Cash Items129.73K196.01K(18.24K)65.54K3.92M
Operating Cash Flow(16.81M)4.92M(25.6M)(40M)(69.81M)
Capital Expenditures(1.2M)(3.36M)(2.05M)(1.54M)(2.9M)
Acquisitions (Net)00000
Purchases of Investments0(114.22M)(97.44M)(208.44M)(151.39M)
Sales of Investments082.51M104.6M93.8M260.6M
Other Investing Activities00000
Investing Cash Flow(1.2M)(35.07M)5.11M(116.18M)97.48M
Debt Repayment00000
Common Stock Issued20.17M4.8M25.52M152.32M248.89M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities50.56K70.3K64.6K450.17K296
Financing Cash Flow20.23M4.87M25.58M152.77M248.89M
Effect of Forex Changes00000
Net Change in Cash2.22M(25.28M)5.09M(3.41M)276.56M
Free Cash Flow(18.01M)1.56M(27.64M)(41.53M)(72.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$105.0M
+ D&A$1.9M
+ Stock-Based Comp$17.2M
+ Deferred Tax$0
+ Working Capital$12.2M
+ Other Non-Cash$3.9M
= Operating Cash Flow-$69.8M
- Capex-$2.9M
= Free Cash Flow-$72.7M

Analysis

FY2025 free cash flow is -$72.7M. FCF conversion is 69.2% of net income. Operating cash flow was -$69.8M, with capex of -$2.9M. The largest bridge item is Stock-Based Comp at $17.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 14, 2026
SC 13GSC 13G filingSep 14, 2026

Does CAPR generate free cash flow?

Capricor Therapeutics, Inc. (CAPR) generated -$72.72M of free cash flow in fiscal 2025.

How much operating cash flow does CAPR produce?

Operating cash flow was -$69.81M, before capital expenditures of $2.90M.